U.S. Stocks End Lower as Earnings Season Begins – The Wall Street Journal

Investors say that while support from the Federal Reserve helped the market climb out of the lows it hit earlier in the year, the economy’s recovery will likely be uneven and prolonged.

“Getting back to growth levels that we’re used to historically is going to take some time,” said Zach Abraham, chief investment officer of Bulwark Capital Management.

He added that the tumult of the past few months has created some potential buying opportunities for the firm within beaten-down sectors like retail.

The Dow Jones Industrial Average fell 157.71 points, or 0.5%, to 28679.81, snapping a four-session streak of gains.

The S&P 500 lost 22.29 points, or 0.6%, to 3511.93 and Nasdaq Composite edged down 12.36 points, or 0.1%, to 11863.90.

Earnings drove swings within the industrial sector Tuesday, with Delta Air Lines DAL -2.67% shares falling 87 cents, or 2.7%, to $31.77 after it posted a steep drop in sales for the most recent quarter and warned that the coronavirus would likely cut into demand for travel for years.

Other airline stocks fell in tandem, with American Airlines AAL -5.42% dropping 70 cents, or 5.4%, to $12.22 and United Airlines Holdings slipping $1.12, or 3.1%, to $35.26.

Financial stocks also came under pressure following a string of quarterly reports.

JPMorgan JPM -1.62% Chase shares fell $1.66, or 1.7%, to $100.78 after it posted earnings above expectations, but also said it would extend the suspension on stock repurchases at least through the end of the fourth quarter.

Shares of Citigroup C -4.80% lost $2.20, or 4.8%, to $43.68, posting their biggest one-day percentage decline in about a month, after the bank reported profit declined 34% from the same period last year.

BlackRock bucked the trend, though, adding $24.07, or 3.9%, to $638.96 after it reported a third-quarter profit that was above expectations and revenue that rose above forecasts.

News about potential vaccines for the coronavirus also moved markets Tuesday.

Johnson & Johnson JNJ -2.29% shares slid $3.48, or 2.3%, to $148.36 after it halted its coronavirus vaccine trials due to a participant becoming unexpectedly sick, prompting fresh speculation about when immunization shots may become widely available. The company also raised its full-year expectations for adjusted operational sales in its earnings report.

J&J’s vaccine is one of the most advanced Covid-19 shots in development and is among just a handful that had entered the last stage of testing in the U.S. The company said Tuesday that it hoped to figure out whether it would be able to resume the trial within a few days.

This is the second time such a trial has been put on hold over a safety concern: AstraZeneca AZN -1.43% has since resumed its testing efforts in the U.K., but its clinical trials in the U.S. remain suspended.

“It’s a reminder that while we have this race to get a vaccine, it could actually take longer,” said Paul Jackson, global head of asset-allocation research at Invesco.

People are also being too optimistic over how quickly a vaccine can halt the pandemic, he cautioned.

“If we get one through the trials and authorized, that would be a great step, but then it will still take quite some time to get it widely distributed,” he said.

Overseas, the pan-continental Stoxx Europe 600 fell 0.6%.

In Asia, most major benchmarks were mixed. The Shanghai Composite Index was flat after trade data showed that Chinese exports rose nearly 10% in September, reflecting a continuing recovery. Markets in Hong Kong were closed due to Tropical Storm Nangka being slated to hit the city.

The International Monetary Fund also released an updated outlook for global economic growth, as finance ministers and central bankers gather virtually for the IMF and World Bank’s annual meetings. It raised its forecasts for 2020, saying that it now expects the downturn to be less severe than it thought in June.

Write to Anna Hirtenstein at anna.hirtenstein@wsj.com and Akane Otani at akane.otani@wsj.com